Pharmaceutical company Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) revealed on Monday that Vibativ (telavancin) is effective in treating secondary bacterial infections in COVID-19 patients and particularly those with obesity, diabetes and heart disease.

According to the company, the five case studies in its dossier illustrate that once-daily dosing of telavancin can effectively and safely treat HABP or VABP due to Gram-positive infection among COVID-19 patients.

The company said Vibativ is a patented, US FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including HABP and VABP that can result from COVID-19, flu and other infections as well as complicated skin and skin structure infections.

In addition, the dossier of patient case studies outlines five real-world instances where the company's Vibativ effectively and safely treated hospital-acquired and ventilator-associated bacterial pneumonia in COVID-19 patients. These types of pneumonia result from serious staph infections, including methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA).

Dr Joseph Reilly, a clinical pharmacist specialist at AtlantiCare Regional Medical Center in Pomona, NJ, provided two COVID-19 patient cases for Cumberland's dossier. Both patients had diabetes, heart disease and underlying health conditions. One patient presented with MSSA hospital-acquired bacterial pneumonia and the other with MRSA ventilator-associated bacterial pneumonia (VABP). Within 48 hours of switching antibiotic therapy to telavancin, blood cultures were clear of MSSA and MRSA.